Table 2 Patient and disease... | American Society of Hematology

Table 2

Patient and disease characteristics according to NOTCH1 mutational status

	All patients		NOTCH1				P
	No.	%	Wild-type		Mutated
	No.	%	No.	%	No.	%
Total no.	123	100	109	89	14	11
Age at diagnosis, y
Median	65.0		64.0		67.5		.960
Range	31-89		31-89		44-81
Sex
Female	36	29	32	29	4	29
Male	87	71	77	71	10	71	1.000
Biopsy
Diagnostic	113	92	100	92	13	93
Progression	10	8	9	8	1	7	1.000
Histology
Typical	102	83	90	83	12	86
Blastoid/pleomorphic	15	12	13	12	2	14	1.000*
Unknown	6	5	6	6	0	0
Stage at diagnosis
I or II	17	14	15	14	2	14
III or IV	99	80	88	81	11	79	1.000*
Unknown	7	6	6	6	1	7
IPI at diagnosis
Low risk (0 and 1)	39	32	35	32	4	29
Intermediate risk (2 and 3)	62	50	55	51	7	50
High risk (4 and 5)	22	18	19	17	3	21	.923
Primary treatment
R-high-dose chemotherapy	22	18	21	19	1	7
R-combination chemotherapy	35	29	28	26	7	50
Combination chemotherapy	23	19	21	19	2	14
Other	19	15	18	17	1	7
Observed	17	14	15	14	2	14	.340*
Unknown	7	6	6	6	1	7
Response to primary treatment
Complete, partial, or stable	89	72	79	73	10	71
None or progression	27	22	24	22	3	21	1.000
Unknown	7	6	6	6	1	7
Median follow-up, mo	51.0		51.0		40.4		.651
Median PFS, y	1.66		1.90		0.88		.065
Median OS, y	3.23		3.86		1.43		.002

	All patients		NOTCH1				P
	No.	%	Wild-type		Mutated
	No.	%	No.	%	No.	%
Total no.	123	100	109	89	14	11
Age at diagnosis, y
Median	65.0		64.0		67.5		.960
Range	31-89		31-89		44-81
Sex
Female	36	29	32	29	4	29
Male	87	71	77	71	10	71	1.000
Biopsy
Diagnostic	113	92	100	92	13	93
Progression	10	8	9	8	1	7	1.000
Histology
Typical	102	83	90	83	12	86
Blastoid/pleomorphic	15	12	13	12	2	14	1.000*
Unknown	6	5	6	6	0	0
Stage at diagnosis
I or II	17	14	15	14	2	14
III or IV	99	80	88	81	11	79	1.000*
Unknown	7	6	6	6	1	7
IPI at diagnosis
Low risk (0 and 1)	39	32	35	32	4	29
Intermediate risk (2 and 3)	62	50	55	51	7	50
High risk (4 and 5)	22	18	19	17	3	21	.923
Primary treatment
R-high-dose chemotherapy	22	18	21	19	1	7
R-combination chemotherapy	35	29	28	26	7	50
Combination chemotherapy	23	19	21	19	2	14
Other	19	15	18	17	1	7
Observed	17	14	15	14	2	14	.340*
Unknown	7	6	6	6	1	7
Response to primary treatment
Complete, partial, or stable	89	72	79	73	10	71
None or progression	27	22	24	22	3	21	1.000
Unknown	7	6	6	6	1	7
Median follow-up, mo	51.0		51.0		40.4		.651
Median PFS, y	1.66		1.90		0.88		.065
Median OS, y	3.23		3.86		1.43		.002

Significance test done excluding “unknown” cases.